Novavax Earnings Call Signals Leaner, Partner-Led Future

Novavax ((NVAX)) has held its Q4 earnings call. Read on for the main highlights of the call.

Novavax’s latest earnings call struck a notably upbeat tone, as management framed 2025 as a turning point toward a leaner, partner‑driven model. Executives highlighted strong revenue growth, a move into profitability, a solid cash runway into 2028, and deepening alliances with Pfizer, Sanofi, Takeda and others, while warning that future upside now depends heavily on partner execution and regulatory outcomes.

Strong Revenue Growth

Novavax reported full‑year 2025 revenue of $1.1 billion, up 65% year over year, underscoring a powerful rebound from prior periods. Fourth‑quarter revenue rose 67% to $147 million, showing that momentum accelerated into year‑end despite a challenging vaccine market backdrop.

Profitability Achieved

The company delivered positive operating and net income for both the fourth quarter and full‑year 2025, marking a key inflection after years of losses. Management framed this shift as evidence that its restructuring, portfolio pruning and partner‑centric model are beginning to translate into sustainable financial performance.

Major Non‑dilutive Capital and Cash Position

Over the last 18 months, Novavax secured more than $800 million in nondilutive capital from partnerships and asset monetizations, strengthening its balance sheet without issuing new equity. It ended 2025 with $857 million in cash and receivables, then added $80 million in early 2026 and believes this provides a funding runway into 2028.

Partnership Momentum and High‑Value Deals

Partnerships are now central to Novavax’s story, led by a January 2026 Pfizer license deal with $30 million upfront and up to $500 million in potential milestones plus multi‑decade royalties across two disease areas. The company also hit all $225 million in Sanofi milestones in 2025 and disclosed multiple new collaborations, including oncology‑focused work and expanded relationships with large pharma names.

Commercial & Market Traction via Partners

On the commercial front, partners are doing the heavy lifting: Takeda has driven more than 12% market share for Nuvaxovid in Japan, while Serum Institute has distributed over 30 million doses of the R21/Matrix‑M malaria vaccine in Africa. Sanofi reported encouraging Phase I/II data for its flu/COVID combination programs, positioning that franchise for a full commercialization cycle in 2026–2027.

Substantial Cost Reductions and Run‑Rate Improvement

Cost discipline was a major theme, with non‑GAAP R&D and SG&A, net of partner reimbursements, down 42% in Q4 and 53% for 2025 versus the prior year. Management said Q4’s expense base implies an annualized run rate of about $328 million, and it is targeting non‑GAAP combined R&D and SG&A of $325 million in 2026, falling to $225 million in 2027 and $200 million or less in 2028.

Revenue Outperformance vs Framework

Novavax’s 2025 non‑GAAP adjusted revenue of $1.1 billion came in roughly $50 million above the midpoint of its prior framework, demonstrating better‑than‑expected execution. The upside was driven by incremental Nuvaxovid product sales, Matrix‑M supply sales, higher royalties and additional R&D reimbursements from Sanofi.

Pipeline and R&D Progress

Beyond commercial vaccines, the company is advancing several preclinical programs, including candidates for C. diff, shingles and an RSV triple combination. Management aims to move at least one internal asset into the clinic as early as 2027 and is also working on Matrix‑M life‑cycle projects and new Matrix‑based adjuvants, including applications in non‑infectious diseases such as oncology.

Manufacturing Rationalization Cash Monetization

Novavax continued to shrink and monetize its manufacturing footprint, selling its Czech Republic facility to Novo Nordisk for $200 million and transferring a U.S. site and equipment to AstraZeneca for $60 million. These deals not only generated immediate cash but are expected to reduce future operating costs by up to $230 million.

Revenue Composition Includes Large Noncash Items

Management cautioned that a sizeable portion of 2025 revenue reflects noncash items tied to prior advance purchase agreement resolutions. Roughly $625 million of revenue came from primarily noncash recognition related to Nuvaxovid supply contracts in Canada and New Zealand, highlighting that part of the reported growth is one‑time and not a recurring cash driver.

Dependence on Partner Execution for Future Value

Looking ahead, Novavax’s long‑term revenue and profit outlook hinges on how well partners deliver, especially Sanofi’s progress on flu/COVID combinations and its role in Nuvaxovid commercialization. The company explicitly tied the timing and magnitude of future royalties and milestones to Sanofi’s development success, regulatory clearances and market execution.

Milestones Excluded or Timing Uncertain

Management underscored that its current 2026 planning remains conservative, excluding a potential $125 million Sanofi milestone linked to Phase III initiation. A separate $75 million technology transfer milestone is also not counted for 2026, as Sanofi requested that some tech transfer work be completed at a new U.S. site, creating uncertainty around when that payment could be realized.

Near‑term Non‑reimbursed Commitments and Front‑loaded Spend

Despite its cost‑cutting progress, Novavax expects some front‑loaded spending in 2026 tied to existing commitments to partners and legacy contracts. These include roughly $125 million of non‑reimbursed R&D and support for Sanofi and about $25 million of COVID strain‑change and commercial manufacturing support across 2026–2027, costs that sit on top of the reduced core run rate.

Regulatory and Macro Uncertainty

Management flagged the broader U.S. regulatory and policy environment as a key wild card, pointing to shifting recommendations and public health priorities that influence vaccine demand. Decisions by advisory bodies and changing public attitudes could impact Nuvaxovid uptake and the overall vaccine market trajectory, adding an external layer of volatility to the outlook.

Competitive and Execution Risks for R&D Programs

Novavax’s early‑stage pipeline also faces typical scientific, competitive and execution risks, particularly in crowded arenas such as shingles and RSV. Timelines for moving candidates into the clinic depend on data quality and potential partner interest, with management indicating it will be selective and strategic in what it discloses to avoid giving rivals an edge.

Guidance and Forward‑Looking Outlook

For 2026, Novavax guided to adjusted total revenue of $230 million to $270 million, comprised of modest Nuvaxovid product and supply sales plus a larger share from licensing, royalties and noncash amortization. Non‑GAAP R&D and SG&A are expected to narrow to about $325 million in 2026 and $225 million in 2027, with a $200 million or lower target in 2028, and with its current cash and credit, the company believes it can self‑fund operations into 2028 while aiming for non‑GAAP profitability around that time.

Novavax’s earnings call painted a picture of a company that has stabilized its finances and repositioned around partnerships after a turbulent pandemic era. While meaningful risks remain around partner performance, milestone timing and regulatory uncertainty, investors heard a clearer path toward a leaner cost base, royalty‑driven revenues and the potential for durable profitability later this decade.